224 related articles for article (PubMed ID: 21463116)
1. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.
Tallman MS
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():65-8. PubMed ID: 21463116
[TBL] [Abstract][Full Text] [Related]
2. Cladribine in hairy cell leukemia.
Belani R; Saven A
Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
[TBL] [Abstract][Full Text] [Related]
3. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
Rucińska M; Machaczka M; Załuska A; Skotnicki AB
Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
5. Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia.
Chihara D; Arons E; Stetler-Stevenson M; Yuan CM; Wang HW; Zhou H; Raffeld M; Xi L; Steinberg SM; Feurtado J; James L; Wilson W; Braylan RC; Calvo KR; Maric I; Dulau-Florea A; Kreitman RJ
J Clin Oncol; 2020 May; 38(14):1527-1538. PubMed ID: 32109194
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
7. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
Zák P; Chrobák L; Dĕdic K; Podzimek K
Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
[TBL] [Abstract][Full Text] [Related]
8. Chemo-immunotherapy for hairy cell leukemia.
Ravandi F
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(0 2):72-4. PubMed ID: 21417822
[TBL] [Abstract][Full Text] [Related]
9. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia.
Mhawech-Fauceglia P; Oberholzer M; Aschenafi S; Baur A; Kurrer M; Von Rohr A; Hsu-Schmitz SF; Wagner B; Delacretaz F; Hurwitz N;
Arch Pathol Lab Med; 2006 Mar; 130(3):374-7. PubMed ID: 16519567
[TBL] [Abstract][Full Text] [Related]
10. Immunoconjugates in the management of hairy cell leukemia.
Kreitman RJ; Pastan I
Best Pract Res Clin Haematol; 2015 Dec; 28(4):236-45. PubMed ID: 26614902
[TBL] [Abstract][Full Text] [Related]
11. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Huynh E; Sigal D; Saven A
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():12-7. PubMed ID: 19814692
[TBL] [Abstract][Full Text] [Related]
12. [Hairy cell leukemia. An alternative method for the detection of minimal residual disease using flow cytometry].
Bengio R; Narbaitz M; Palacios F; Scolnik M; Sarmiento M
Medicina (B Aires); 2000; 60 Suppl 2():71-6. PubMed ID: 11188936
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
[TBL] [Abstract][Full Text] [Related]
14. Development of cladribine at Scripps for hairy cell leukemia and current results.
Torrey ML; Sigal DS; Saven A
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():29-33. PubMed ID: 21504293
[TBL] [Abstract][Full Text] [Related]
15. Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.
Else M; Dearden CE; Matutes E; Forconi F; Lauria F; Ahmad H; Kelly S; Liyanage A; Ratnayake V; Shankari J; Whalley I; Catovsky D
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():75-8. PubMed ID: 21504288
[TBL] [Abstract][Full Text] [Related]
16. My treatment approach to hairy cell leukemia.
Naik RR; Saven A
Mayo Clin Proc; 2012 Jan; 87(1):67-76. PubMed ID: 22212971
[TBL] [Abstract][Full Text] [Related]
17. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up.
Gidron A; Tallman MS
Leuk Lymphoma; 2006 Nov; 47(11):2301-7. PubMed ID: 17107901
[TBL] [Abstract][Full Text] [Related]
18. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
[TBL] [Abstract][Full Text] [Related]
19. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
[TBL] [Abstract][Full Text] [Related]
20. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]